GSK plc (LSE:GSK) entered into an agreement to acquire Aiolos Bio, Inc. from a group of shareholders for $1.4 billion on January 8, 2024. Under the terms of the agreement, GSK will pay a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments. In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Hengrui. This transaction is subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US and expected to close in the first quarter of 2024. Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor for GSK.

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders on February 14, 2024.